 <h1>Ibsrela Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>tenapanor</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about tenapanor. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ibsrela.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tenapanor: oral tablets</i></p><h3>Warning</h3><p><ul>
<li>
Contraindicated in pediatric patients &lt;6 years of age; avoid use in children 6 to &lt;12 years of age.&lt;sup&gt;1&lt;/sup&gt;  Tenapanor caused deaths, presumably due to dehydration, in young juvenile rats.&lt;sup&gt;1&lt;/sup&gt;  (See Pediatric Use under Cautions.)</li></ul></p><ul>
<li>
Contraindicated in pediatric patients &lt;6 years of age; avoid use in children 6 to &lt;12 years of age.&lt;sup&gt;1&lt;/sup&gt;  Tenapanor caused deaths, presumably due to dehydration, in young juvenile rats.&lt;sup&gt;1&lt;/sup&gt;  (See Pediatric Use under Cautions.)</li></ul><p>
<li>
Safety and efficacy not established in patients &lt;18 years of age.&lt;sup&gt;1&lt;/sup&gt;</li></p><p></p><p>Side effects include:</p><p>Diarrhea, abdominal distension, flatulence, dizziness. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tenapanor: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects included diarrhea, abdominal distention, flatulence, and dizziness.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 20%)</p><p><b>Common</b> (1% to 10%): Abdominal distention, flatulence, severe diarrhea</p><p><b>Frequency not reported</b>: Abnormal gastrointestinal sounds, rectal bleeding<sup>[Ref]</sup></p><p>Diarrhea occurred in 20% of patients with renal dysfunction (estimated glomerular function rate [eGFR] less than 90 mL/min/1.73 m2), compared to 16% of patients without renal dysfunction.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hyperkalemia resulting in hospitalization<sup>[Ref]</sup></p><p>In a clinical trial with patients with type 2 diabetes mellitus and chronic kidney disease (eGFR 25 to 70 mL/min/1.73 m2), hyperkalemia resulting in hospitalization was reported in 2 patients given this drug and 1 patient given placebo.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ibsrela (tenapanor)." Ardelyx, Inc, Fremont, CA. </p><h2>More about Ibsrela (tenapanor)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug class: NHE3 inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ibsrela &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Irritable Bowel Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>